Clinical-stage biopharmaceutical company DBV Technologies (Euronext Paris:DBV) (Nasdaq Capital Market:DBVT) on Friday announced a financing agreement of up to USD306.9m (EUR284.5m), including USD125.5m (EUR116.3m) upfront and up to USD181.4m (EUR168.2m) contingent on the full exercise of warrants.
These funds will support the preparation and submission of a Biologics License Application (BLA) for the Viaskin peanut patch, for the treatment of peanut allergy in children aged 4 to 7, and its potential US commercial launch. The financing will result in an immediate dilution of 22.4%, rising to 73.7% if all warrants are exercised.
The financing was led by MPM BioImpact, Adage Capital Management LP, Janus Henderson Investors, Vivo Capital and other healthcare-focused funds.
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema